Berlanga J - Search Results

1

Disposition and receptor-site binding of (125)I-EGF after topical administration to skin wounds.

Prats PA, Duconge J, Valenzuela C, Berlanga J, Edrosa CR, Fernández-Sánchez E. Prats PA, et al. Among authors: berlanga j. Biopharm Drug Dispos. 2002 Mar;23(2):67-76. doi: 10.1002/bdd.299. Biopharm Drug Dispos. 2002. PMID: 11932961

2

Prophylactic use of epidermal growth factor reduces ischemia/reperfusion intestinal damage.

Berlanga J, Prats P, Remirez D, Gonzalez R, Lopez-Saura P, Aguiar J, Ojeda M, Boyle JJ, Fitzgerald AJ, Playford RJ. Berlanga J, et al. Am J Pathol. 2002 Aug;161(2):373-9. doi: 10.1016/S0002-9440(10)64192-2. Am J Pathol. 2002. PMID: 12163361 Free PMC article.

3

Epidermal growth factor protects against carbon tetrachloride-induced hepatic injury.

Berlanga J, Caballero ME, Ramirez D, Torres A, Valenzuela C, Lodos J, Playford RJ. Berlanga J, et al. Clin Sci (Lond). 1998 Mar;94(3):219-23. doi: 10.1042/cs0940219. Clin Sci (Lond). 1998. PMID: 9616254

4

Heberprot-P: a novel product for treating advanced diabetic foot ulcer.

Berlanga J, Fernández JI, López E, López PA, del Río A, Valenzuela C, Baldomero J, Muzio V, Raíces M, Silva R, Acevedo BE, Herrera L. Berlanga J, et al. MEDICC Rev. 2013 Jan;15(1):11-5. doi: 10.37757/MR2013V15.N1.4. MEDICC Rev. 2013. PMID: 23396236 Free article.

5

[The role of the epidermal growth factor in cell and tissue protection].

Berlanga J, Caballero E, Prats P, López Saura P, Playford RJ. Berlanga J, et al. Med Clin (Barc). 1999 Sep 4;113(6):222-9. Med Clin (Barc). 1999. PMID: 10472612 Review. Spanish. No abstract available.

6

Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers.

Cabrales A, Gil J, Fernández E, Valenzuela C, Hernández F, García I, Hernández A, Besada V, Reyes O, Padrón G, Berlanga J, Guillén G, González LJ. Cabrales A, et al. Among authors: berlanga j. Eur J Pharm Sci. 2013 Jan 23;48(1-2):40-6. doi: 10.1016/j.ejps.2012.10.006. Epub 2012 Oct 23. Eur J Pharm Sci. 2013. PMID: 23099431 Clinical Trial.

7

Safety Evaluation of Transgenic Tilapia with Accelerated Growth.

Guillén I I, Berlanga J, Valenzuela CM, Morales A, Toledo J, Estrada MP, Puentes P, Hayes O, de la Fuente J. Guillén I I, et al. Among authors: berlanga j. Mar Biotechnol (NY). 1999 Jan;1(1):2-14. doi: 10.1007/pl00011746. Mar Biotechnol (NY). 1999. PMID: 10373604

8

Attenuation of internal organ damages by exogenously administered epidermal growth factor (EGF) in burned rodents.

Berlanga J, Lodos J, López-Saura P. Berlanga J, et al. Burns. 2002 Aug;28(5):435-42. doi: 10.1016/s0305-4179(02)00023-2. Burns. 2002. PMID: 12163282

9

Epidermal growth factor reduces multiorgan failure induced by thioacetamide.

Caballero ME, Berlanga J, Ramirez D, Lopez-Saura P, Gozalez R, Floyd DN, Marchbank T, Playford RJ. Caballero ME, et al. Among authors: berlanga j. Gut. 2001 Jan;48(1):34-40. doi: 10.1136/gut.48.1.34. Gut. 2001. PMID: 11115820 Free PMC article.

10

Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds.

Berlanga J, Cibrian D, Guillén I, Freyre F, Alba JS, Lopez-Saura P, Merino N, Aldama A, Quintela AM, Triana ME, Montequin JF, Ajamieh H, Urquiza D, Ahmed N, Thornalley PJ. Berlanga J, et al. Clin Sci (Lond). 2005 Jul;109(1):83-95. doi: 10.1042/CS20050026. Clin Sci (Lond). 2005. PMID: 15755259

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

92 results

Search Page

Filters